Filing Overview
Registrant: I-MAB, a foreign private issuer headquartered in Shanghai, China. The provided metadata identifies “Novabridge Biosciences,” but the filing text identifies the registrant as I-MAB.
Form and period: Form 6-K covering the month of May 2020, filed May 28, 2020. Commission File Number 001-39173. The registrant indicates that it files annual reports on Form 20-F.
Financial and Operating Information
The provided filing text consists of the Form 6-K cover page and an exhibit index. It does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes and Outlook
The filing text does not describe material changes versus a prior comparable period, management guidance, business outlook, risks, contingencies, or unusual items.
The filing lists Exhibit 99.1 as a press release, but the press release content was not included in the provided source text.
Investor Verification Items
- Confirm that I-MAB, rather than Novabridge Biosciences, is the intended registrant.
- Obtain and review Exhibit 99.1, the referenced press release, for the substantive disclosure.
- Verify any financial results, operational developments, guidance, or risk disclosures against the complete Form 6-K and the registrant’s Form 20-F filings.